U.K. joining regulatory consortium as Brexit deadline looms 

In a further sign that MHRA is preparing for its newfound independence, the U.K. drugs regulator is banding together with the Australia, Canada, Singapore and Switzerland Consortium to review products simultaneously in all five countries, reducing duplication and providing timely access to products.

With the addition of the U.K., the ACSS Consortium becomes the Access Consortium, which will cooperate to review regulatory applications for innovative and generic medicines. ...